The online version of this article (doi:10.1186/1477-7819-10-170) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
Rong BX and Yang SY participated in the design and coordination of the study, carried out the critical appraisal of the studies, statistical analysis of the studies and wrote the manuscript. Li W, Zhang W, and Ming ZJ developed the literature search, carried out the extraction of data, assisted in the critical appraisal of included studies and assisted in writing up. All authors read and approved the final manuscript.
Many studies have investigated the efficacy of Endostar combined with platinum-based doublet chemotherapy (PBDC) versus PBDC alone for treating advanced non-small cell lung cancer (NSCLC). This study is a meta-analysis of available evidence.
Fifteen studies reporting Endostar combined with PBDC versus PBDC alone for treating advanced NSCLC were reviewed. Pooled odds ratios and hazard ratio with 95% confidence intervals were calculated using either the fixed effects model or random effects model.
The overall response rate (ORR) and disease control rate (DCR) of Endostar combined with PBDC for treating NSCLC were significantly higher than those of PBDC alone, with 14.7% and 13.5% improvement, respectively (P < 0.00001). In addition, the time to progression (TTP) and quality of life (QOL) were improved after the treatment of Endostar combined with PBDC (P < 0.00001). The main adverse effects found in this review were hematological reactions, hepatic toxicity, and nausea/vomiting. Endostar combined with PBDC had a similar incidence of adverse reactions compared with PBDC alone (P < 0.05).
Endostar combined with PBDC was associated with higher RR, DCR, and TTP as well as superior QOL profiles compared with PBDC alone. Endostar combined with PBDC had a similar incidence of adverse reactions compared with PBDC alone.
Authors’ original file for figure 112957_2012_1146_MOESM1_ESM.jpeg
Authors’ original file for figure 212957_2012_1146_MOESM2_ESM.jpeg
Authors’ original file for figure 312957_2012_1146_MOESM3_ESM.jpeg
Authors’ original file for figure 412957_2012_1146_MOESM4_ESM.jpeg
Authors’ original file for figure 512957_2012_1146_MOESM5_ESM.jpeg
Authors’ original file for figure 612957_2012_1146_MOESM6_ESM.jpeg
Authors’ original file for figure 712957_2012_1146_MOESM7_ESM.jpeg
Authors’ original file for figure 812957_2012_1146_MOESM8_ESM.jpeg
Novello S, Le Chevalier T: Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. Oncology (Williston Park, NY). 2003, 17: 357-364.
Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001, 19: 3210-3218. PubMed
Novello S, Pimentel FL, Douillard JY, O’Brien M, von Pawel J, Eckardt J, Liepa AM, Simms L, Visseren-Grul C, Paz-Ares L: Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010, 5: 1602-1608. 10.1097/JTO.0b013e3181eaf30f. CrossRefPubMed
Ling Y, Yang Y, Lu N, You Q, Wang S, Gao Y, Chen Y, Guo QL: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 2007, 361: 79-84. 10.1016/j.bbrc.2007.06.155. CrossRefPubMed
Cirocchi R, D’Ajello F, Trastulli S, Santoro A, Di Rocco G, Vendettuoli D, Rondelli F, Giannotti D, Sanguinetti A, Minelli L, Redler A, Basoli A, Avenia N: Meta-analysis of thyroidectomy with ultrasonic dissector versus conventional clamp and tie. World J Surg Oncol. 2010, 8: 112-10.1186/1477-7819-8-112. PubMedCentralCrossRefPubMed
Wang J, Sun Y, Liu Y, Yu Q, Zhang Y, Li K, Zhu Y, Zhou Q, Hou M, Guan Z: Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi. 2005, 8: 283-290. PubMed
Yang L, Wang JW, Cui CX, Hang J, Zang HP, Li ST, Sun Y: Rh-endostatin(YH-16) in combination with vinorelbine and cisplatin for advanced non-small cell lung cancer:a multicenter phase II trial. Chin J New Drugs. 2005, 14: 204-207.
Cai L, Sun LC, Yang CY, Men QW, Pang H, Sui GJ: Observation on the efficacy of endostar combined with Chemotherapy in the treatment of non-small cell lung cancer. Chinese J Pract Int Med. 2007, 27: 1541-1542.
Mu HY, Shen CY, Feng YL: Clinical observation on the target therapy of rh-endostin, combined with chemotherapy in advanced non-small cell lung cancer. Zhongguo Fei ai Za Zhi. 2009, 12: 780-784. PubMed
Liao HY, Feng WN, Li Y, Zang J, Cai SW, Chen HG, Sun JP, Wei YM, Gu LJ: Study of the feasibility of endostar plus gemcitabine and cisplatin regimen for advanced non-small-cell lung cancer. Zhongguo Fei Ai Za Zhi. 2009, 12: 574-576.
Zhang T, Liu DH, Wang B, Li XY: Latest efficacy and safety of YH-16 combined with GP for advanced non-small cell lung cancer. Chin General Pract. 2009, 12: 969-971.
Liu J, Huang JZ, Quan JZ, Liu Y, Dong MX: Clinical study of concurrent chemoradiotherapy combined with YH-16 in the treatment of local advanced non-small cell lung cancer. Chin Med Herald. 2009, 6: 253-254.
Ma J, Yang J, Li Z, Li F, Huang D, Yan G, Wang J, Lang J: A randomized clinical trail of endostar combined with concurrent chemoradiotherapy in treatment of local advanced non-small cell lung cancer. J Clin Med Pract. 2009, 13: 20-21.
Shi GY, Su YH: The clinical observation of Endostar injection combined with GP regimen in advanced non-small cell lung cancer. Journal of Medical Forum. 2009, 30: 53-54.
Han B, Xiu Q, Wang H, Shen J, Gu A, Luo Y, Bai C, Guo S, Liu W, Zhuang Z: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol. 2011, 6: 1104-1109. 10.1097/JTO.0b013e3182166b6b. CrossRefPubMed
Hu HT, Gong CM, Zeng LJ, Zhang T: Recombinant human endostatin combined with topotecan plus cisplatin regimen for advanced small-cell lung cancer. Journal of Regional Anatomy and Operative Surgery. 2011, 20: 190-191.
Wen F, Wang W, Shang LQ, Li XC, Liu JJ: Observation of short term effects of endostar combined with NP regimen for non-small cell lung cancer. Journal of Clinical Medicine in Practice. 2011, 15: 79-80.
Zhang H, Qi R: Clinical study of chemotherapy combined with endostar in the treatment of advanced non-small cell lung cancer. Journal of Xinjiang Medical University. 2011, 34: 533-535.
Chen Q, Xie Q, Shi Q, Xiao S: Short-term efficacy of YH-16 combined with GP regimen for advanced non-small cell lung cancer. Cancer Research on Prevention and Treatment. 2011, 38: 199-201.
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009, 27: 1227-1234. 10.1200/JCO.2007.14.5466. CrossRefPubMed
Sun Y, Wang J, Liu Y, Song X, Zhang Y, Li K, Zhu Y, Zhou Q, You L, Yao C: Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol (Meeting Abstracts). 2005, 23: 7138-
Han B, Xiu Q, Wang H: 2008. J Clin Oncol (Meeting Abstracts). 2008, 26: 19126-
Kabbinavar FF, Wallace JF, Holmgren E, Yi J, Cella D, Yost KJ, Hurwitz HI: Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. Oncologist. 2008, 13: 1021-1029. 10.1634/theoncologist.2008-0003. CrossRefPubMed
- Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer
- BioMed Central
Neu im Fachgebiet Chirurgie
e.Med Kampagnen-Visual, Mail Icon II